Arbutin protects brain against middle cerebral artery occlusion-reperfusion (MCAo/R) injury.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
05 11 2021
Historique:
received: 02 08 2021
accepted: 02 09 2021
pubmed: 11 9 2021
medline: 27 11 2021
entrez: 10 9 2021
Statut: ppublish

Résumé

Focal ischemia causes irreversible brain damage if cerebral blood flow is not restored promptly. Acute phase excitotoxicity and pro-oxidant and inflammatory events in the sub-chronic phase elicit coagulative necrosis, vascular injury, cerebral oedema, and neurobehavioral deficits. Earlier, in pre-clinical studies arbutin protected behavioral functions and improved therapeutic outcomes in different models of brain and metabolic disorders. Arbutin is natural hydroquinone that might protect against ischemia-reperfusion (I/R) injury. In this study, cerebro-protective effects of arbutin were evaluated in the middle cerebral artery occlusion-reperfusion (MCAo/R) mouse model. Mice were administered arbutin (50, 100 mg/kg, i.p.) for 21 days, and subjected to MCAo/R or sham surgery on day 14. Results showed brain infarction, blood-brain barrier dysfunction, oedema, and neurological deficits 24 h post-MCAo/R injury that were prevented by arbutin. Behavioral evaluations over the sub-chronic phase revealed MCAo/R triggered spatial and working memory deficits. Arbutin protected the memory against MCAo/R injury and decreased hydroxy-2'-deoxyguanosine, protein carbonyls, inflammatory cytokines (tumor necrosis factor-α, myeloperoxidase, matrix metalloproteinase-9, inducible nitric oxide synthase), and enhanced glutathione levels in the ischemia ipsilateral hemisphere. Arbutin decreased brain acetylcholinesterase activity, glutamate, and enhanced GABA levels against MCAo/R. Arbutin can alleviate I/R pathogenesis and protects neurobehavioral functions in the MCAo/R mouse model.

Identifiants

pubmed: 34507065
pii: S0006-291X(21)01294-8
doi: 10.1016/j.bbrc.2021.09.006
pii:
doi:

Substances chimiques

Neuroprotective Agents 0
Neurotransmitter Agents 0
Glutamic Acid 3KX376GY7L
gamma-Aminobutyric Acid 56-12-2
Arbutin C5INA23HXF

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-57

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Manish Kumar (M)

Chitkara College of Pharmacy, Chitkara University, Punjab, India; Department of Pharmacology, Swift School of Pharmacy, Rajpura, Patiala, Punjab, India. Electronic address: mkpharmacology@gmail.com.

Gurteg Singh (G)

Department of Pharmacology, Swift School of Pharmacy, Rajpura, Patiala, Punjab, India.

Ajay Singh Kushwah (AS)

Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Ropar, Punjab, India.

Gurunath Surampalli (G)

Bharat Institute of Technology (BIT), Ibrahimpatnam, Hyderabad, India.

Thakur Gurjeet Singh (TG)

Chitkara College of Pharmacy, Chitkara University, Punjab, India.

Sushma Gupta (S)

Department of Pharmacology, Swift School of Pharmacy, Rajpura, Patiala, Punjab, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH